B4313
(E/Z)-BCI hydrochloride
≥98% (HPLC)
동의어(들):
(E)-2-benzylidene-3-(cyclohexylamino)-2,3-dihydro-1H-inden-1-one; 3-(cyclohexylamino)-2,3-dihydro-2-(phenylmethylene)-1Hinden-1-one; 2-benzylidene-3-(cyclohexylamino)-1-Indanone hydrochloride, NSC 150117 hydrochloride
조직 및 계약 가격을 보려면 로그인를 클릭합니다.
크기 선택
제품정보 (DICE 배송 시 비용 별도)
실험식(Hill 표기법):
C22H23NO · HCl
CAS 번호:
Molecular Weight:
353.89
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
51111800
MDL number:
InChI key
JPATUDRDKCLPTI-UHFFFAOYSA-N
SMILES string
Cl.O=C1C(=Cc2ccccc2)C(NC3CCCCC3)c4ccccc14
InChI
1S/C22H23NO.ClH/c24-22-19-14-8-7-13-18(19)21(23-17-11-5-2-6-12-17)20(22)15-16-9-3-1-4-10-16;/h1,3-4,7-10,13-15,17,21,23H,2,5-6,11-12H2;1H
assay
≥98% (HPLC)
form
powder
storage condition
desiccated
color
white to beige
solubility
DMSO: 10 mg/mL, clear
storage temp.
2-8°C
Quality Level
Application
(E/Z)-BCI hydrochloride has been used:
- to evaluate the role of the Duox-H2O2-Dusp6 derepression signaling pathway in heart regeneration
- as an MKP-1 inhibitor to investigate the role of MKP-1 on bexarotent-induced effects
- as a dual specificity phosphatase 6 (DUSP6) inhibitor to study its effects on the proliferation of SKOV3 cells
Biochem/physiol Actions
(E/Z)-BCI Hydrochloride is an inhibitor of dual-specificity phosphatase 6 (Dusp6) and Dusp1; hyperactivates FGF signaling.
BCI is an allosteric inhibitor of Dusp6 that acts within the phosphatase domain to prevent the catalytic stimulation of phosphatase activity induced by ERK2 substrate binding. BCI also hyperactivates FGF signaling, since Dusp6 functions as a feedback regulator of FGF signaling.
저장 등급
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
HE4 Compromises Cytotoxic Mononuclear Cells via Inducing Dual Specificity Phosphatase 6
James NE, et al.
Frontiers in Pharmacology, 10, 216-216 (2019)
Bexarotent attenuated CCI-induced spinal neuroinflammation and neuropathic pain by targeting MKP-1
Gui Y, et al.
The Journal of Pain : Official Journal of the American Pain Society (2019)
Guifang Gan et al.
Theranostics, 11(12), 6006-6018 (2021-04-27)
Objectives: Sorafenib is the only FDA-approved first-line target drug for HCC patients. However, sorafenib merely confers 3-5 months of survival benefit with less than 30% of HCC patients sensitive to sorafenib therapy. Thus, it's necessary to develop a sensitizer for
Yulong Gui et al.
The journal of pain, 21(11-12), 1149-1159 (2019-01-21)
It is widely accepted that neuroinflammation in the spinal cord contributes to the development of central sensitization in neuropathic pain. Mitogen-activated protein kinase (MAPK) activation plays a vital role in the development of neuroinflammation in the spinal cord. In this
Nicole E James et al.
Frontiers in pharmacology, 10, 216-216 (2019-04-04)
While selective overexpression of serum clinical biomarker Human epididymis secretory protein 4 (HE4) is indicative of ovarian cancer tumorigenesis, much is still known about the mechanistic role of the HE4 gene or gene product. Here, we examine the role of
자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..
고객지원팀으로 연락바랍니다.